Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover

Cancer Research

Volumn 71, Issue 8, 2011, Pages 3042-3051

  Milhollen, Michael A ^a   Narayanan, Usha ^a   Soucy, Teresa A ^a   Veiby, Petter O ^a   Smith, Peter G ^a   Amidon, Benjamin ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CULLIN; CULLIN RING LIGASE; LIGASE; NEDD8 ACTIVATING ENZYME; REPLICATION LICENSING FACTOR CDT1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE; CONTROLLED STUDY; DNA REPAIR; DNA REPLICATION; DNA REREPLICATION; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL;

APOPTOSIS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CULLIN PROTEINS; CYCLOPENTANES; DNA DAMAGE; DNA REPLICATION; DNA, NEOPLASM; GENE KNOCKDOWN TECHNIQUES; HCT116 CELLS; HUMANS; PYRIMIDINES; RNA, SMALL INTERFERING; S PHASE; UBIQUITINS;

EID: 79954611863     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-2122     Document Type: Article

References (50)

1. Welchman RL, Gordon C, Mayer RJ. Ubiquitin and ubiquitin-like proteins as multifunctional signals. Nat Rev Mol Cell Biol 2005;6: 599-609. (Pubitemid 41081264)
2. Hershko A. The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle. Cell Death Differ 2005;12:1191-7. (Pubitemid 41195103)
3. Kerscher O, Felberbaum R, Hochstrasser M. Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu Rev Cell Dev Biol 2006;22:159-80.
4. Yeh ET, Gong L, Kamitani T. Ubiquitin-like proteins: New wines in new bottles. Gene 2000;248:1-14. (Pubitemid 30259196)
5. Herrmann J, Lerman LO, Lerman A. Ubiquitin and ubiquitin-like proteins in protein regulation. Circ Res 2007;100:1276-91. (Pubitemid 46742918)
6. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998;67:425-79. (Pubitemid 28411135)
7. Gong L, Yeh ET. Identification of the activating and conjugating enzymes of the NEDD8 conjugation pathway. J Biol Chem 1999;274: 12036-42.
8. Huang DT, Ayrault O, Hunt HW, Taherbhoy AM, Duda DM, Scott DC, et al. E2-RING expansion of the NEDD8 cascade confers specificity to cullin modification. Mol Cell 2009;33:483-95.
9. Pan ZQ, Kentsis A, Dias DC, Yamoah K, Wu K. Nedd8 on cullin: Building an expressway to protein destruction. Oncogene 2004;23: 1985-97. (Pubitemid 38496728)
10. Soucy TA, Smith PG, Rolfe M. Targeting NEDD8-activated cullin- RING ligases for the treatment of cancer. Clin Cancer Res 2009;15: 3912-6.
11. Petroski MD, Deshaies RJ. Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol 2005;6:9-20. (Pubitemid 40064895)
12. Podust VN, Brownell JE, Gladysheva TB, Luo RS, Wang C, Coggins MB, et al. A Nedd8 conjugation pathway is essential for proteolytic targeting of p27Kip1 by ubiquitination. Proc Natl Acad Sci U S A 2000;97:4579-84. (Pubitemid 30238600)
13. Read MA, Brownell JE, Gladysheva TB, Hottelet M, Parent LA, Coggins MB, et al. Nedd8 modification of cul-1 activates SCF(beta (TrCP))-dependent ubiquitination of IkappaBalpha. Mol Cell Biol 2000;20:2326-33. (Pubitemid 30152040)
14. Duda DM, Borg LA, Scott DC, Hunt HW, Hammel M, Schulman BA. Structural insights into NEDD8 activation of cullin-RING ligases: Conformational control of conjugation. Cell 2008;134:995-1006.
15. Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009;458:732-6.
16. Arias EE, Walter JC. Replication-dependent destruction of Cdt1 limits DNA replication to a single round per cell cycle in Xenopus egg extracts. Genes Dev 2005;19:114-26. (Pubitemid 40095821)
17. Bell SP, Dutta A. DNA replication in eukaryotic cells. Annu Rev Biochem 2002;71:333-74. (Pubitemid 34800224)
18. Remus D, Beuron F, Tolun G, Griffith JD, Morris EP, Diffley JF. Concerted loading of Mcm2-7 double hexamers around DNA during DNA replication origin licensing. Cell 2009;139:719-30.
19. Kim Y, Kipreos ET. Cdt1 degradation to prevent DNA rereplication: Conserved and non-conserved pathways. Cell Div 2007;2:18-27.
20. Melixetian M, Ballabeni A, Masiero L, Gasparini P, Zamponi R, Bartek J, et al. Loss of Geminin induces rereplication in the presence of functional p53. J Cell Biol 2004;165:473-82. (Pubitemid 38679613)
21. Saxena S, Dutta A. Geminin and p53: Deterrents to rereplication in human cancer cells. Cell Cycle 2003;2:283-6.
22. Vaziri C, Saxena S, Jeon Y, Lee C, Murata K, Machida Y, et al. A p53- dependent checkpoint pathway prevents rereplication. Mol Cell 2003;11:997-1008. (Pubitemid 36566321)
23. Fujita M. Cdt1 revisited: Complex and tight regulation during the cell cycle and consequences of deregulation in mammalian cells. Cell Div 2006;1:22.
24. Lin JJ, Dutta A. ATR pathway is the primary pathway for activating G2/ M checkpoint induction after rereplication. J Biol Chem 2007;282: 30357-62. (Pubitemid 350041546)
25. Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999;1:193-9. (Pubitemid 129500937)
26. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269:682-5.
27. Wang W, Nacusi L, Sheaff RJ, Liu X. Ubiquitination of p21Cip1/WAF1 by SCFSkp2: Substrate requirement and ubiquitination site selection. Biochemistry 2005;44:14553-64. (Pubitemid 41567463)
28. Margottin-Goguet F, Hsu JY, Loktev A, Hsieh HM, Reimann JD, Jackson PK. Prophase destruction of Emi1 by the SCF(betaTrCP/ Slimb) ubiquitin ligase activates the anaphase promoting complex to allow progression beyond prometaphase. Dev Cell 2003;4:813-26. (Pubitemid 36676034)
29. Lin DI, Barbash O, Kumar KG, Weber JD, Harper JW, Klein-Szanto AJ, et al. Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF(FBX4-alphaB crystallin) complex. Mol Cell 2006;24:355-66. (Pubitemid 44647901)
30. Ye X, Nalepa G, Welcker M, Kessler BM, Spooner E, Qin J, et al. Recognition of phosphodegron motifs in human cyclin E by the SCF (Fbw7) ubiquitin ligase. J Biol Chem 2004;279:50110-9. (Pubitemid 39577823)
31. Hu J, McCall CM, Ohta T, Xiong Y. Targeted ubiquitination of CDT1 by the DDB1-CUL4A-ROC1 ligase in response to DNA damage. Nat Cell Biol 2004;6:1003-9. (Pubitemid 39359854)
32. Nishitani H, Sugimoto N, Roukos V, Nakanishi Y, Saijo M, Obuse C, et al. Two E3 ubiquitin ligases, SCF-Skp2 and DDB1-Cul4, target human Cdt1 for proteolysis. EMBO J 2006;25:1126-36. (Pubitemid 43372125)
33. Kim J, Feng H, Kipreos ET. C. elegans CUL-4 prevents rereplication by promoting the nuclear export of CDC-6 via a CKI-1-dependent pathway. Curr Biol 2007;17:966-72. (Pubitemid 46829838)
34. Mendez J, Zou-Yang XH, Kim SY, Hidaka M, Tansey WP, Stillman B. Human origin recognition complex large subunit is degraded by ubiquitin-mediated proteolysis after initiation of DNA replication. Mol Cell 2002;9:481-91. (Pubitemid 34273780)
35. Zhao H, Piwnica-Worms H. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol Cell Biol 2001;21:4129-39. (Pubitemid 32565295)
36. Lee AY, Liu E, Wu X. The Mre11/Rad50/Nbs1 complex plays an important role in the prevention of DNA rereplication in mammalian cells. J Biol Chem 2007;282:32243-55. (Pubitemid 350106413)
37. Davidson IF, Li A, Blow JJ. Deregulated replication licensing causes DNA fragmentation consistent with head-to-tail fork collision. Mol Cell 2006;24:433-43. (Pubitemid 44647903)
38. Lau E, Chiang GG, Abraham RT, Jiang W. Divergent S phase checkpoint activation arising from prereplicative complex deficiency controls cell survival. Mol Biol Cell 2009;20:3953-64.
39. Liu E, Lee AY, Chiba T, Olson E, Sun P, Wu X. The ATR-mediated S phase checkpoint prevents rereplication in mammalian cells when licensing control is disrupted. J Cell Biol 2007;179:643-57. (Pubitemid 350146252)
40. Lin JJ, Milhollen MA, Smith PG, Narayanan U, Dutta A. NEDD8- targeting drug MLN4924 elicits DNA rereplication by stabilizing CDT1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Res 2010;70:10310-20.
41. Handeli S, Weintraub H. The ts41 mutation in Chinese hamster cells leads to successive S phases in the absence of intervening G2, M, and G1. Cell 1992;71:599-611.
42. Sugimoto N, Yoshida K, Tatsumi Y, Yugawa T, Narisawa-Saito M, Waga S, et al. Redundant and differential regulation of multiple licensing factors ensures prevention of rereplication in normal human cells. J Cell Sci 2009;122:1184-91.
43. Senga T, Sivaprasad U, Zhu W, Park JH, Arias EE, Walter JC, et al. PCNA is a cofactor for Cdt1 degradation by CUL4/DDB1-mediated Nterminal ubiquitination. J Biol Chem 2006;281:6246-52. (Pubitemid 43847555)
44. Zhu W, Chen Y, Dutta A. Rereplication by depletion of geminin is seen regardless of p53 status and activates a G2/M checkpoint. Mol Cell Biol 2004;24:7140-50. (Pubitemid 39014440)
45. Nishitani H, Lygerou Z. Control of DNA replication licensing in a cell cycle. Genes Cells 2002;7:523-34. (Pubitemid 34679050)
46. Archambault V, Ikui AE, Drapkin BJ, Cross FR. Disruption of mechanisms that prevent rereplication triggers a DNA damage response. Mol Cell Biol 2005;25:6707-21. (Pubitemid 41023243)
47. Green BM, Li JJ. Loss of rereplication control in Saccharomyces cerevisiae results in extensive DNA damage. Mol Biol Cell 2005;16: 421-32. (Pubitemid 40024322)
48. Zhu W, Dutta A. An ATR- and BRCA1-mediated Fanconi anemia pathway is required for activating the G2/M checkpoint and DNA damage repair upon rereplication. Mol Cell Biol 2006;26:4601-11. (Pubitemid 43877578)
49. Tercero JA, Longhese MP, Diffley JF. A central role for DNA replication forks in checkpoint activation and response. Mol Cell 2003;11:1323-36. (Pubitemid 36645150)
50. Skaar JR, Pagano M. Control of cell growth by the SCF and APC/C ubiquitin ligases. Curr Opin Cell Biol 2009;21:816-24.